Founded by scientists and entrepreneurs in 2002, GenomeScan is a public privately-owned company based in Leiden, The Netherlands. GenomeScan leads the way in Next Generation Sequencing (NGS) services as it develops and provides customizable NGS solutions for the pharmaceutical industry, biotech and agricultural companies, health care providers and academic institutions. GenomeScan’s services portfolio encompasses the latest sequencing and array technologies including gene expression analysis (at tissue or single cell level), whole genome sequencing (WGS), whole exome sequencing (WES), disease panels, and epigenetics (e.g. DNA methylation).
GenomeScan is engaged in developing new tools to diagnose genetic disorders quicker, affordably and more effectively, fostering product innovation through partnership with medical centers and research laboratories. We believe that NGS applications can offer novel options for the diagnosis of genetic disorders, improve disease risk management, and accelerate access to personalized medicine.
Our commitment to excellence is reflected in our employees, work ethic and technologies. Employees have different scientific backgrounds and have experienced the practical challenges associated with genetic assay development. From the wealth of technical possibilities, they will select the optimal solution, provide scientific guidance and help tailor projects to fit the customer needs.
GenomeScan has always embraced quality challenges and obtained ISO/IEC 17025 [L518] and ISO 15189 [M308] accreditations for its services. The company data management system adheres to the European directives on personal data protection and privacy. Our outstanding quality assurance allows customers to have absolute confidence and trust.